Johnson & Johnson Profit Beats Estimates on Drug Sales

Johnson & Johnson, the world’s biggest maker of health-care products, reported third-quarter profit that beat analysts’ estimates as newer drugs continue to propel the company to faster growth than competitors. J&J raised its full-year forecast.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.